Opendata, web and dolomites

SHIGETECVAX SIGNED

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SHIGETECVAX project word cloud

Explore the words cloud of the SHIGETECVAX project. It provides you a very rough idea of what is the project "SHIGETECVAX" about.

entails    populations    advancing    generations    radically    efforts    mucosal    virulence    epidemiology    surface    burden    costly    pillars    vaccination    natural    gut    ing    shigella    administration    etec    oral    protection    complementary    invasion    failed    bangladesh    diarrhoea    human    safer    rational    neutralizing    safety    additional    elimination    reactogenic    huge    adults    disease    lmics    multiple    closely    serotypes    vaccine    critical    vaccines    recognition    immunity    immune    antibodies    enteric    designed    protecting    induce    although    antigen    pathogen    reduce    material    infections    attenuated    shigetec    disruption    manufacture    possibly    lps    endemic    molecular    live    detoxified    almost    invasiveness    solution    antigens    shared    pathogens    doses    shigellosis    first    too    candidates    immunogenicity    clinical    cell    caused    blocking    sero    attempts    trial    toxin    advantage    expertise    immunodominant   

Project "SHIGETECVAX" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN VACCINE INITIATIVE EWIV 

Organization address
address: VOSSSTRASSE 2 GEB 4040
city: HEIDELBERG
postcode: 69115
website: http://www.euvaccine.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 0 €
 EC max contribution 8˙603˙989 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE EWIV DE (HEIDELBERG) coordinator 359˙755.00
2    EVELIQURE BIOTECHNOLOGIES GMBH AT (WIEN) participant 5˙024˙401.00
3    INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH BD (DHAKA) participant 1˙924˙713.00
4    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 749˙842.00
5    PATH US (SEATTLE) participant 545˙277.00

Map

 Project objective

Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SHIGETECVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SHIGETECVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More